{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T10:08:27Z","timestamp":1775902107525,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00115-018-0607-0","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T08:29:26Z","timestamp":1538036966000},"page":"1388-1399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antik\u00f6rpertestung","MOG encephalomyelitis: international recommendations on diagnosis and antibody testing"],"prefix":"10.1007","volume":"89","author":[{"given":"S.","family":"Jarius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. C.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Franciotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Palace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Trebst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. G.","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"607_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","volume":"293","author":"T Akaishi","year":"2016","unstructured":"Akaishi T, Nakashima I, Takeshita T et\u00a0al (2016) Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J\u00a0Neuroimmunol 293:28\u201333","journal-title":"J Neuroimmunol"},{"key":"607_CR2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","volume":"57","author":"M Andersson","year":"1994","unstructured":"Andersson M, Alvarez-Cermeno J, Bernardi G et al (1994) Cerebrospinal fluid in the diagnosis of multiple sclerosis: a\u00a0consensus report. J\u00a0Neurol Neurosurg Psychiatr 57:897\u2013902","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"607_CR3","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1111\/j.1537-2995.2010.02766.x","volume":"50","author":"DM Arnold","year":"2010","unstructured":"Arnold DM, Crowther MA, Meyer RM et\u00a0al (2010) Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a\u00a0clinical trial of rituximab in immune thrombocytopenia. Transfusion 50:2577\u20132581","journal-title":"Transfusion"},{"key":"607_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00415-018-8781-3","volume":"265","author":"M Baumann","year":"2018","unstructured":"Baumann M, Grams A, Djurdjevic T et\u00a0al (2018) MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J\u00a0Neurol 265:845\u2013855","journal-title":"J Neurol"},{"key":"607_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jns.2017.08.3254","volume":"381","author":"M Bouzar","year":"2017","unstructured":"Bouzar M, Daoudi S, Hattab S et al (2017) Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: clinical and paraclinical characteristics in Algerian patients. J\u00a0Neurol Sci 381:240\u2013244","journal-title":"J Neurol Sci"},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","volume":"2","author":"K Chalmoukou","year":"2015","unstructured":"Chalmoukou K, Alexopoulos H, Akrivou S et al (2015) Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2:e131","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"607_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1177\/1352458515591071","volume":"22","author":"\u00c1 Cobo-Calvo","year":"2016","unstructured":"Cobo-Calvo \u00c1, Ruiz A, Poulat A\u2011L et al (2016) MOG-antibody-related disorders cohort description: common features and uncommon presentations. Mult Scler 22:405","journal-title":"Mult. Scler."},{"key":"607_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jns.2016.02.022","volume":"363","author":"A Cortese","year":"2016","unstructured":"Cortese A, Franciotta D, Alfonsi E et\u00a0al (2016) Combined central and peripheral demyelination: clinical features, diagnostic findings, and treatment. J\u00a0Neurol Sci 363:182\u2013187","journal-title":"J Neurol Sci"},{"key":"607_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","volume":"138","author":"F Pauli Di","year":"2011","unstructured":"Di Pauli F, Mader S, Rostasy K et al (2011) Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 138:247\u2013254","journal-title":"Clin Immunol"},{"key":"607_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.msard.2018.01.007","volume":"20","author":"S Fan","year":"2018","unstructured":"Fan S, Xu Y, Ren H et al (2018) Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Mult Scler Relat Disord 20:144\u2013152","journal-title":"Mult Scler Relat Disord"},{"key":"607_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00415-017-8716-4","volume":"265","author":"J Frau","year":"2018","unstructured":"Frau J, Villar LM, Sardu C et\u00a0al (2018) Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a\u00a0prognostic factor? J\u00a0Neurol 265:424\u2013430","journal-title":"J Neurol"},{"key":"607_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1046\/j.1537-2995.1987.27688071707.x","volume":"27","author":"L Garcia","year":"1987","unstructured":"Garcia L, Huh YO, Fischer HE et al (1987) Positive immunohematologic and serologic test results due to high-dose intravenous immune globulin administration. Transfusion 27:503","journal-title":"Transfusion"},{"issue":"4","key":"607_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 75(4):478\u2013487","journal-title":"JAMA Neurol."},{"key":"607_CR14","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","volume":"21","author":"R Hoftberger","year":"2015","unstructured":"Hoftberger R, Sepulveda M, Armangue T et\u00a0al (2015) Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 21:866\u2013874","journal-title":"Mult Scler"},{"key":"607_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(15)00313-0","volume":"15","author":"R Hohlfeld","year":"2016","unstructured":"Hohlfeld R, Dornmair K, Meinl E et al (2016) The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol 15:317\u2013331","journal-title":"Lancet Neurol"},{"key":"607_CR16","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P et al (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131:3072\u20133080","journal-title":"Brain"},{"key":"607_CR17","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1182\/blood-2005-12-019604","volume":"109","author":"S Jarius","year":"2007","unstructured":"Jarius S, Eichhorn P, Albert MH et al (2007) Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a\u00a0TNFalpha-dependent and Fc-receptor-independent way. Blood 109:4376\u20134382","journal-title":"Blood"},{"key":"607_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00415-016-8360-4","volume":"264","author":"S Jarius","year":"2017","unstructured":"Jarius S, Eichhorn P, Franciotta D et al (2017) The MRZ reaction as a\u00a0highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J\u00a0Neurol 264:453\u2013466","journal-title":"J Neurol"},{"issue":"5","key":"607_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1515\/CCLM.2010.127","volume":"48","author":"S Jarius","year":"2010","unstructured":"Jarius S, Franciotta D, Bergamaschi R et al (2010) IgM antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med 48(5):659\u2013663","journal-title":"Clin Chem Lab Med"},{"key":"607_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Kleiter I, Ruprecht K et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50 patients. Part 3: brainstem involvement \u2013 frequency, presentation and outcome. J\u00a0Neuroinflammation 13:281","journal-title":"J Neuroinflammation"},{"key":"607_CR21","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","volume":"22","author":"S Jarius","year":"2016","unstructured":"Jarius S, Metz I, Konig FB et al (2016) Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u2018pattern II multiple sclerosis\u2019 and brain biopsy findings in a\u00a0MOG-IgG-positive case. Mult Scler 22:1541\u20131549","journal-title":"Mult Scler"},{"key":"607_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius S, Paul F, Franciotta D et al (2011) Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J\u00a0Neurol Sci 306:82\u201390","journal-title":"J Neurol Sci"},{"key":"607_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J\u00a0Neuroinflammation 13:280","journal-title":"J Neuroinflammation"},{"key":"607_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J\u00a0Neuroinflammation 13:279","journal-title":"J Neuroinflammation"},{"key":"607_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Ruprecht K, Stellmann JP et al (2018) MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a\u00a0multicenter study of 200 patients and review of the literature. J\u00a0Neuroinflammation 15:88. \n                    https:\/\/doi.org\/10.1186\/s12974-018-1108-6","journal-title":"J Neuroinflammation"},{"key":"607_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B et\u00a0al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J\u00a0Neuroinflammation 9:14","journal-title":"J Neuroinflammation"},{"key":"607_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bpa.12084","volume":"23","author":"S Jarius","year":"2013","unstructured":"Jarius S, Wildemann B (2013) Aquaporin-4 antibodies (NMO-IgG) as a\u00a0serological marker of neuromyelitis optica: a\u00a0critical review of the literature. Brain Pathol 23:661\u2013683","journal-title":"Brain Pathol"},{"key":"607_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Geraldes R, Probert F et al (2017) Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain 140:617\u2013627","journal-title":"Brain"},{"key":"607_CR29","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a\u00a0UK study. Brain 140:3128\u20133138","journal-title":"Brain"},{"key":"607_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","volume":"88","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Tackley G, Kong Y et al (2017) Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J\u00a0Neurol Neurosurg Psychiatr 88:132\u2013136","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"607_CR31","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","volume":"2","author":"SM Kim","year":"2015","unstructured":"Kim SM, Woodhall MR, Kim JS et\u00a0al (2015) Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2:e163","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"607_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1212\/WNL.0000000000001749","volume":"85","author":"I Kister","year":"2015","unstructured":"Kister I, Paul F (2015) Pushing the boundaries of neuromyelitis optica: does antibody make the disease? Neurology 85:118\u2013119","journal-title":"Neurology"},{"key":"607_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a\u00a0comparative study. JAMA Neurol 71:276\u2013283","journal-title":"JAMA Neurol."},{"key":"607_CR34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a\u00a0neuromyelitis optica phenotype. Neurology 79:1273\u20131277","journal-title":"Neurology"},{"key":"607_CR35","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/archneur.65.11.1527","volume":"65","author":"FB Konig","year":"2008","unstructured":"Konig FB, Wildemann B, Nessler S et\u00a0al (2008) Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol 65:1527\u20131532","journal-title":"Arch Neurol"},{"key":"607_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K et\u00a0al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J\u00a0Neuroinflammation 8:184","journal-title":"J Neuroinflammation"},{"key":"607_CR37","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","volume":"264","author":"S Mariotto","year":"2017","unstructured":"Mariotto S, Ferrari S, Monaco S et al (2017) Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a\u00a0multicenter study. J\u00a0Neurol 264:2420\u20132430","journal-title":"J Neurol"},{"key":"607_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/01658107.2015.1072726","volume":"39","author":"R Matsuda","year":"2015","unstructured":"Matsuda R, Kezuka T, Umazume A et al (2015) Clinical profile of anti-myelin oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis. Neuroophthalmology 39:213\u2013219","journal-title":"Neuroophthalmology"},{"key":"607_CR39","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","volume":"80","author":"L Matthews","year":"2013","unstructured":"Matthews L, Marasco R, Jenkinson M et\u00a0al (2013) Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80:1330\u20131337","journal-title":"Neurology"},{"key":"607_CR40","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","volume":"191","author":"MC Mayer","year":"2013","unstructured":"Mayer MC, Breithaupt C, Reindl M et\u00a0al (2013) Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J\u00a0Immunol 191:3594\u20133604","journal-title":"J Immunol"},{"key":"607_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jns.2015.05.013","volume":"355","author":"MA Mealy","year":"2015","unstructured":"Mealy MA, Whetstone A, Orman G et\u00a0al (2015) Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J\u00a0Neurol Sci 355:59\u201363","journal-title":"J Neurol Sci"},{"key":"607_CR42","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1177\/1352458508096878","volume":"14","author":"DH Miller","year":"2008","unstructured":"Miller DH, Weinshenker BG, Filippi M et\u00a0al (2008) Differential diagnosis of suspected multiple sclerosis: a\u00a0consensus approach. Mult Scler 14:1157\u20131174","journal-title":"Mult Scler"},{"key":"607_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5692\/clinicalneurol.cn-000756","volume":"56","author":"T Miyazaki","year":"2016","unstructured":"Miyazaki T, Nakajima H, Motomura M et\u00a0al (2016) A case of recurrent optic neuritis associated with cerebral and spinal cord lesions and autoantibodies against myelin oligodendrocyte glycoprotein relapsed after fingolimod therapy. Rinsho Shinkeigaku 56:265\u2013269","journal-title":"Rinsho Shinkeigaku"},{"issue":"10","key":"607_CR44","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","volume":"23","author":"A Montcuquet","year":"2016","unstructured":"Montcuquet A, Collongues N, Papeix C et al (2016) Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler 23(10):1377\u20131384","journal-title":"Mult Scler"},{"key":"607_CR45","first-page":"27","volume":"33","author":"Y Nishikawa","year":"2016","unstructured":"Nishikawa Y, Oku H, Tonari K et al (2016) A case of CRION with high titer of MOG antibody. Neuro-Ophthalmol Japan 33:27\u201331","journal-title":"Neuro-Ophthalmol. Japan"},{"key":"607_CR46","first-page":"199","volume":"48","author":"A Oshiro","year":"2016","unstructured":"Oshiro A, Nakamura S, Tamashiro K et al (2016) Anti-MOG + neuromyelitis optica spectrum disorders treated with plasmapheresis. No To Hattatsu 48:199\u2013203","journal-title":"No To Hattatsu"},{"key":"607_CR47","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache F, Zimmermann H, Mikolajczak J et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J\u00a0Neuroinflammation 13:282","journal-title":"J Neuroinflammation"},{"key":"607_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","volume":"14","author":"P Peschl","year":"2017","unstructured":"Peschl P, Schanda K, Zeka B et al (2017) Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J\u00a0Neuroinflammation 14:208","journal-title":"J Neuroinflammation"},{"key":"607_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00415-013-6957-4","volume":"261","author":"A Petzold","year":"2014","unstructured":"Petzold A, Plant GT (2014) Chronic relapsing inflammatory optic neuropathy: a\u00a0systematic review of 122 cases reported. J\u00a0Neurol 261:17\u201326","journal-title":"J Neurol"},{"key":"607_CR50","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","volume":"77","author":"AK Probstel","year":"2011","unstructured":"Probstel AK, Dornmair K, Bittner R et\u00a0al (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77:580\u2013588","journal-title":"Neurology"},{"key":"607_CR51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","volume":"15","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Dale RC, Brilot F (2016) Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a\u00a0serum biomarker for demyelination. Autoimmun Rev 15:307\u2013324","journal-title":"Autoimmun Rev"},{"key":"607_CR52","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","volume":"22","author":"S Ramanathan","year":"2015","unstructured":"Ramanathan S, Prelog K, Barnes EH et al (2016) Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 22:470\u2013482","journal-title":"Mult Scler"},{"key":"607_CR53","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","volume":"1","author":"S Ramanathan","year":"2014","unstructured":"Ramanathan S, Reddel SW, Henderson A et\u00a0al (2014) Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 1:e40","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"607_CR54","first-page":"99","volume":"4","author":"H Reiber","year":"1998","unstructured":"Reiber H (1998) Cerebrospinal fluid \u2013 physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 4:99\u2013107","journal-title":"Mult Scler"},{"key":"607_CR55","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1177\/1352458509348418","volume":"15","author":"H Reiber","year":"2009","unstructured":"Reiber H, Teut M, Pohl D et al (2009) Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult Scler 15:1466\u20131480","journal-title":"Mult Scler"},{"key":"607_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/135245859800400304","volume":"4","author":"H Reiber","year":"1998","unstructured":"Reiber H, Ungefehr S, Jacobi C (1998) The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 4:111\u2013117","journal-title":"Mult Scler"},{"issue":"3","key":"607_CR57","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","volume":"30","author":"M Reindl","year":"2017","unstructured":"Reindl M, Jarius S, Rostasy K et\u00a0al (2017) Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol 30(3):295\u2013301","journal-title":"Curr Opin Neurol"},{"key":"607_CR58","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474\u2013481","journal-title":"Neurology"},{"key":"607_CR59","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","volume":"263","author":"M Sepulveda","year":"2016","unstructured":"Sepulveda M, Armangue T, Martinez-Hernandez E et al (2016) Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J\u00a0Neurol 263:1349\u20131360","journal-title":"J Neurol"},{"key":"607_CR60","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","volume":"3","author":"M Spadaro","year":"2016","unstructured":"Spadaro M, Gerdes LA, Krumbholz M et\u00a0al (2016) Autoantibodies to MOG in a\u00a0distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3:e257","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"607_CR61","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acn3.164","volume":"2","author":"M Spadaro","year":"2015","unstructured":"Spadaro M, Gerdes LA, Mayer MC et al (2015) Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2:295\u2013301","journal-title":"Ann Clin Transl Neurol"},{"key":"607_CR62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/WNO.0b013e318283c3ed","volume":"33","author":"M Storoni","year":"2013","unstructured":"Storoni M, Davagnanam I, Radon M et\u00a0al (2013) Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a\u00a0novel magnetic resonance imaging scoring system. J\u00a0Neuroophthalmol 33:123\u2013127","journal-title":"J Neuroophthalmol"},{"key":"607_CR63","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ana.24117","volume":"75","author":"MJ Titulaer","year":"2014","unstructured":"Titulaer MJ, Hoftberger R, Iizuka T et al (2014) Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 75:411\u2013428","journal-title":"Ann Neurol"},{"key":"607_CR64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.braindev.2014.02.002","volume":"37","author":"RS Tsuburaya","year":"2015","unstructured":"Tsuburaya RS, Miki N, Tanaka K et al (2015) Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a\u00a0Japanese boy with recurrent optic neuritis. Brain Dev 37:145\u2013148","journal-title":"Brain Dev"},{"issue":"3","key":"607_CR65","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/ene.12898","volume":"23","author":"ED Pelt Van","year":"2015","unstructured":"Van Pelt ED, Wong YY, Ketelslegers IA et al (2015) Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol 23(3):580\u2013587","journal-title":"Eur J Neurol"},{"key":"607_CR66","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","volume":"2","author":"P Waters","year":"2015","unstructured":"Waters P, Woodhall M, O\u2019connor KC et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2:e89","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"607_CR67","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1212\/WNL.0000000000004087","volume":"89","author":"B Wildemann","year":"2017","unstructured":"Wildemann B, Jarius S, Schwarz A et al (2017) Failure of alemtuzumab therapy to control mog-igg encephalomyelitis. Neurology 89:207\u2013209. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000004087","journal-title":"Neurology"},{"key":"607_CR68","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et\u00a0al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"607_CR69","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ et\u00a0al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"607_CR70","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","volume":"2","author":"SS Zamvil","year":"2015","unstructured":"Zamvil SS, Slavin AJ (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a\u00a0diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2:e62","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"607_CR71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","volume":"305","author":"L Zhou","year":"2017","unstructured":"Zhou L, Huang Y, Li H et al (2017) MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients. J\u00a0Neuroimmunol 305:19\u201328","journal-title":"J Neuroimmunol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-018-0607-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0607-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0607-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T19:59:59Z","timestamp":1569527999000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-018-0607-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":71,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1007\/s00115-018-0607-0","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"27 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S. Jarius, N.\u00a0Asgari, R.C.\u00a0Dale und J.\u00a0de Seze geben an, dass kein Interessenkonflikt besteht. O.\u00a0Aktas erhielt Forschungsunterst\u00fctzung durch die Deutsche Forschungsgemeinschaft (DFG), das Bundesministerium f\u00fcr Bildung und Forschung (BMBF; KKNMS; f\u00fcr NEMOS NationNMO FKZ 01GI1602) sowie Vortragshonorare und Reisestipendien von Bayer, Biogen, Genzyme, MedImmune, Merck, Novartis, Roche, Sanofi und Teva. D.\u00a0Franciotta erhielt ein Honorar f\u00fcr eine Pr\u00e4sentation von Biogen, die nicht mit der vorliegenden Arbeit in Zusammenhang steht. K.\u00a0Fujihara ist in Beratungsgremien von Bayer Schering Pharma, Biogen Idec, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, Alexion Pharmaceuticals und MedImmune t\u00e4tig; hat von Bayer Schering Pharma, Biogen Idec, Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Asahi Kasei Medical Co., Daiichi Sankyo und Nihon Pharmaceutical Reisekosten und Honorare erhalten; ist in der Redaktion der Zeitschrift <i>Clinical and Experimental Neuroimmunology<\/i>; ist Beiratsmitglied des <i>Sri Lanka Journal of Neurology<\/i> und erhielt Forschungsunterst\u00fctzung von Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, Genzyme Japan, Ministry of Education, Science and Technology of Japan und Ministry of Health, Welfare and Labor of Japan. A.\u00a0Jacob wird von der NHS National Specialised Commissioning Group f\u00fcr NMO unterst\u00fctzt und war Berater f\u00fcr Shire, Alexion, Terumo BCT und Chugai Pharmaceuticals und erhielt Forschungsgelder von Biogen und Alexion Pharmaceuticals. H.J.\u00a0Kim hat Honorare f\u00fcr Vortr\u00e4ge und Beratungst\u00e4tigkeiten erhalten von Bayer Schering Pharma, Biogen, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok und UCB; erhielt Forschungsunterst\u00fctzung durch das Ministry of Science, ICT & Future Planning und akzeptierte Forschungsfinanzierung von Genzyme, Kael-GemVax, Merck Serono, Teva-Handok und UCB; dient einem Lenkungsausschuss f\u00fcr MedImmune; ist Mitherausgeber f\u00fcr die Zeitschrift <i>Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical<\/i> und ein assoziierter Herausgeber f\u00fcr das <i>Journal of Clinical Neurology<\/i>. I.\u00a0Kleiter erhielt Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit von Bayer Schering Pharma, Biogen, Celltrion, Eisai, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Sanofi Genzyme, Teva-Handok und UCB sowie Forschungsunterst\u00fctzung von Ministry of Science & ICT, Sanofi Genzyme, Teva-Handok und UCB. Er ist ferner Mitglied eines Steering Committees von MedImmune und Co-Editor\/assoziierter Editor der folgenden Zeitschriften: <i>Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical<\/i>; <i>Journal of Clinical Neurology<\/i>. T.\u00a0K\u00fcmpfel hat Reisekosten und pers\u00f6nliche Entsch\u00e4digungen von Bayer Healthcare, Teva Pharma, Merck Serono, Novartis, Sanofi Genzyme und Biogen Idec sowie Zusch\u00fcsse von Chugai Pharma und Novartis erhalten. M.\u00a0Levy erh\u00e4lt Unterst\u00fctzung von Quest Diagnostics. J.\u00a0Palace wird teilfinanziert durch einen spezialisierten nationalen Service f\u00fcr Neuromyelitis optica und angeborene Myasthenie. Sie erhielt Unterst\u00fctzung f\u00fcr wissenschaftliche Tagungen und Honorare f\u00fcr Beratungsleistungen von Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma, Bayer Schering, Alexion, Roche, Genzyme, MedImmune, Euroimmun, MedDay, Abide und ARGENX sowie Forschungsunterst\u00fctzung von Merck Serono, Novartis, Biogen Idec, Teva, Abide und Bayer Schering. Ihr Hospital Trust hat Forschungsunterst\u00fctzung erhalten im Rahmen ihrer klinischen T\u00e4tigkeit f\u00fcr den RSS. Sie hat ferner Grants erhalten von der MS Society, der Guthy-Jackson Charitable Foundation, dem NIHR, dem Oxford Health Services Research Committee, EDEN, MRC und John Fell f\u00fcr wissenschaftliche Studien. F.\u00a0Paul erhielt Honorare und Forschungsunterst\u00fctzung von Alexion, Bayer, Biogen, Chugai, Merck Serono, Novartis, Genzyme, MedImmune, Shire, Teva und ist in wissenschaftlichen Beir\u00e4ten f\u00fcr Alexion, MedImmune und Novartis t\u00e4tig. Er erhielt finanzielle Unterst\u00fctzung von der Deutschen Forschungsgemeinschaft (DFG Exc 257), dem Bundesministerium f\u00fcr Bildung und Forschung (Kompetenznetzwerk Multiple Sklerose), der Guthy-Jackson Charitable Foundation, dem EU-Rahmenprogramm\u00a07, und der National Multiple Sclerosis Society der USA. K.\u00a0Ruprecht erhielt Forschungsunterst\u00fctzung vom Bundesministerium f\u00fcr Bildung und Forschung (BMBF\/KKNMS, Kompetenznetzwerk Multiple Sklerose) und Novartis sowie Reisekosten bzw. Vortragsgeb\u00fchren von der Guthy-Jackson Charitable Foundation, Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi-Aventis, Genzyme, Teva Pharmaceuticals und Novartis. A.\u00a0Saiz wird von La Marat\u00f3 de TV3 (20141830) unterst\u00fctzt. C.\u00a0Trebst hat Honorare f\u00fcr Beratung und Gutachten von der Bayer Vital GmbH, der Biogen Idec GmbH, der Genzyme GmbH und Novartis Pharmaceuticals erhalten, die nicht mit der vorliegenden Arbeit in Zusammenhang stehen. B.G.\u00a0Weinshenker erh\u00e4lt Lizenzgeb\u00fchren von RSR Ltd, Universit\u00e4t Oxford, Hospices Civil de Lyon, und MVZ Labor PD Dr. Volkmann und Kollegen GbR f\u00fcr ein Patent zu NMO-IgG als diagnostischen Test f\u00fcr NMO und verwandte Erkrankungen. Er erh\u00e4lt eine pers\u00f6nliche Entsch\u00e4digung f\u00fcr die Mitgliedschaft in einem Ausschuss f\u00fcr klinische Studien bei NMO, der von den Pharmaunternehmen MedImmune und Alexion durchgef\u00fchrt wird. Er ist Berater f\u00fcr Caladrius Biosciences bez\u00fcglich m\u00f6glicher klinischer Studien bei NMO. Er ist Berater f\u00fcr Caladrius Biosciences, Brainstorm Therapeutics, Roivant Sciences und Chugai Pharma hinsichtlich m\u00f6glicher klinischer Studien bei NMO. Er erh\u00e4lt eine pers\u00f6nliche Entsch\u00e4digung f\u00fcr die Teilnahme an einem Data Safety Monitoring Board f\u00fcr Novartis f\u00fcr klinische Studien. Die Arbeit von B.\u00a0Wildemann wurde durch Forschungsbeihilfen der Dietmar-Hopp-Stiftung, von Merck Serono und des Bundesministeriums f\u00fcr Bildung und Forschung (Kompetenznetzwerk Multiple Sklerose) unterst\u00fctzt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}